Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Dow
Moodys
McKesson
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,247,402

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,247,402 protect, and when does it expire?

Patent 8,247,402 protects DORIBAX and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 8,247,402
Title:Crystal form of pyrrolidylthiocarbapenem derivative
Abstract: Novel crystals of a pyrrolidylthiocarbapenem derivative having excellent stability is provided. According to the present invention, a crystal of (+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3[[(3S,5S)-5-(sulfa- moylaminomethyl)p yrrolidin-3-yl]thio]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 13.04, 14.98, 15.88, 16.62, 20.62, 21.06, 22.18, 23.90, 26.08, 28.22 and 28.98 (degrees) and a crystal of said compound having a diffraction pattern in powder X-ray diffraction having main peaks at diffraction angles (2.theta.) of about 6.62, 13.04, 15.44, 16.58, 17.64, 20.88, 23.26, 25.02 and 25.52 (degrees) are provided.
Inventor(s): Saitoh; Izumi (Hyogo, JP), Takahira; Masayuki (Hyogo, JP), Kawakita; Toshio (Hyogo, JP), Yoshioka; Yasuyuki (Hyogo, JP)
Assignee: Shiongi & Co., Ltd. (Osaka, JP)
Application Number:12/012,932
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,247,402
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Process;

Drugs Protected by US Patent 8,247,402

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-002 Oct 5, 2010 DISCN Yes No   Request a Trial   Request a Trial Y Y   Request a Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;INTRAVENOUS 022106-001 Oct 12, 2007 DISCN Yes No   Request a Trial   Request a Trial Y Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,247,402

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-99868Mar 31, 2000

International Family Members for US Patent 8,247,402

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 304014   Request a Trial
Australia 2001244692   Request a Trial
Australia 4469201   Request a Trial
Brazil 0109712   Request a Trial
Brazil PI0109712   Request a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Dow
Merck
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.